LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Начало・Списък с акции・Becton Dickinson and Co

Becton Dickinson and Co

Затворен

СекторЗдравеопазване

147.7 0.8

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

147

Максимум

147.72

Ключови измерители
By Trading Economics
Приходи	-692M -310M
Продажби	-538M 4.7B
P/E Средно за сектора	24.8 49.701
EPS	2.9
Дивидентна доходност	2.91
Марж на печалбата	-6.576
Служители	60,000
EBITDA	-1B 189M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+23.42% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	2.91% 2.39%
Следващи печалби	6.08.2026 г.
Следваща дата на дивидент	30.06.2026 г.
Следваща дата на екс-дивидент	9.06.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-2.4B 39B
Предишно отваряне	146.9
Предишно затваряне	147.7

Настроения в новините

By Acuity

24%

76%

43 / 345 Класиране в Healthcare

Becton Dickinson and Co Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.08.2025 г., 11:19 ч. UTC

Печалби

Becton Dickinson Boosts Outlook as 3Q Results Beat Estimates

14.07.2025 г., 14:26 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14.07.2025 г., 11:08 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14.07.2025 г., 10:37 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

7.08.2025 г., 10:32 ч. UTC

Печалби

Becton Dickinson Expects to Complete Remaining $250M of $1B Share-Buyback Commitment by End FY25 >BDX

7.08.2025 г., 10:31 ч. UTC

Печалби

Becton Dickinson Backs FY25 View of Rev $21.8B-$21.9B >BDX

7.08.2025 г., 10:31 ч. UTC

Печалби

Becton Dickinson Had Seen FY25 Adjusted EPS $14.06-$14.34 >BDX

7.08.2025 г., 10:30 ч. UTC

Печалби

Becton Dickinson Raises FY25 View To Adj EPS $14.30-Adj EPS $14.45 >BDX

7.08.2025 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q Adj EPS $3.68 >BDX

7.08.2025 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q Net $574M >BDX

7.08.2025 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q Rev $5.51B >BDX

7.08.2025 г., 10:30 ч. UTC

Печалби

Becton Dickinson 3Q EPS $2.00 >BDX

15.07.2025 г., 18:32 ч. UTC

Придобивния, сливания и поглъщания

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15.07.2025 г., 18:31 ч. UTC

Придобивния, сливания и поглъщания

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14.07.2025 г., 16:12 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14.07.2025 г., 15:06 ч. UTC

Придобивния, сливания и поглъщания

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14.07.2025 г., 14:11 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14.07.2025 г., 10:53 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14.07.2025 г., 10:22 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14.07.2025 г., 10:22 ч. UTC

Придобивния, сливания и поглъщания

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14.07.2025 г., 10:22 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14.07.2025 г., 10:21 ч. UTC

Придобивния, сливания и поглъщания

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14.07.2025 г., 10:20 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14.07.2025 г., 10:19 ч. UTC

Придобивния, сливания и поглъщания

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14.07.2025 г., 10:19 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14.07.2025 г., 10:18 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14.07.2025 г., 10:18 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14.07.2025 г., 10:17 ч. UTC

Придобивния, сливания и поглъщания

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14.07.2025 г., 10:16 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14.07.2025 г., 10:16 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

Сравнение с други в отрасъла

Ценова промяна

Becton Dickinson and Co Прогноза

Ценова цел

By TipRanks

23.42% нагоре

12-месечна прогноза

Среден 182.2 USD 23.42%

Висок 221 USD

Нисък 159 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Becton Dickinson and Co през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Becton Dickinson and Co през последните 3 месеца.

Настроение

By Acuity

43 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.